secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vitro Biopharma, Inc. (—)
CIK:        0000793171
Form:       8-K
Filed at:   2024-01-23T23:59:59+00:00
Accession:  0001493152-24-003346
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vitro Biopharma appoints Thomas Ohrt as CFO; former CFO Nathan Haas to consult
------------------------------------------------------------------------------

- Nathan Haas resigned as CFO effective Jan 18, 2024; entered into Settlement and Consulting Agreements.
- Haas to receive $175k unpaid bonus upon qualified financing or direct listing; 2023 bonus by April 1, 2024.
- Haas will serve as strategy consultant for four months at $15,000/month.
- Thomas Ohrt appointed CFO, salary $250k/year, eligible for $125k target performance bonus.
- Ohrt served as controller since Jan 2021; 35 years of financial leadership experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/793171/000149315224003346/0001493152-24-003346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/793171/000149315224003346/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-003346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer